https://www.selleckchem.com/products/SB590885.html
Histone deacetylase inhibitors (HDACi) are used to treat patients with cutaneous T-cell lymphoma (CTCL), but they show limited efficacy. Hence, combination therapies should be explored to enhance the effectiveness of HDACis. This study was conducted to identify novel therapeutic targets that can be combined with HDACis for treating CTCL. We performed a global kinome profiling assay of three CTCL cell lines (HH, MJ, and Hut78) with three HDACis (romidepsin, vorinostat, and belinostat) using the PamChip® microarray. The three cell lines
Me gusta
Comentario
Compartir
